daratumumab + teclistamab + ciltacabtagene autoleucel

daratumumab + teclistamab + ciltacabtagene autoleucel is an investigational, multi‑agent immunotherapy strategy for multiple myeloma that combines an anti‑CD38 monoclonal antibody (daratumumab), a BCMA×CD3 bispecific T‑cell–engaging antibody (teclistamab), and a BCMA‑directed CAR‑T cell therapy (ciltacabtagene autoleucel). Daratumumab targets CD38 on myeloma and immunosuppressive cells to induce direct and immune‑mediated cytotoxicity and to favorably remodel the immune microenvironment.[4] Teclistamab binds BCMA on myeloma cells and CD3 on T cells, forming an immunologic synapse that redirects and activates endogenous T cells to lyse BCMA‑expressing plasma cells.[2][6][8] Ciltacabtagene autoleucel is an autologous CAR‑T cell product engineered to recognize BCMA and mediate potent, durable T‑cell–driven cytotoxicity against myeloma cells. This combination and related sequencing regimens (for example in aMMbition and similar studies) are being explored to deepen responses and potentially achieve functional cure in newly diagnosed or relapsed/refractory multiple myeloma by layering complementary BCMA‑targeted and immune‑modulating mechanisms.[1][3][5][7][9][13]